AbelZeta Pharma

Clinical Trials

Currently we are performing clinical investigations of novel CAR-T and TIL therapies in multiple disease areas including hematological malignancies, solid tumors and inflammatory and immunological diseases.

Product Indication Clinical Study NCT NUMBER(s) PUBLICATION/PRESENTATION
C-CAR031 Hepatocellular Carcinoma (HCC) Phase I/II trial in China NCT06590246 AACR Abstract 04/2023

AACR Poster 04/2023
C-CAR039 r/r B-NHL Investigator-initiated trial in China NCT04317885

ASCO 2021 Abstract

ASCO 2021 Presentation

ASH 2023 Paper

ASH 2023 Presentation

NCT04655677
NCT04696432
NCT04693676
Phase 1b/2 trial in China NCT05800977  
Phase 1b trial worldwide (ex-Greater China) licensed to JNJ NCT05421663  
C-CAR066 r/r B-NHL including prior CAR-T Investigator-initiated trial in China NCT04036019

ASCO 2021 Abstract

ASCO 2021 Presentation

ASH 2023 Paper

ASH 2023 Poster

Phase 1b trial worldwide (ex-Greater China) licensed to JNJ NCT05784441  
C-CAR168 Autoimmune Diseases (Lupus Nephritis and SLE) Investigator-initiated trial in China NCT06249438 ACR Convergence 2024 Presentation
Scroll to Top